Reduction in the expression of CTL and NK cell markers on ex vivo–isolated spleen cells upon anti-ASGM-1 treatment in vivo
| Host . | % Reduction in positive cells after α-ASGM-1 depletion . | ||
|---|---|---|---|
| CD8+ . | CD8+ASGM1+ . | DX5+ . | |
| Naive | 17.5 | 20.1 | 55.3 |
| Sp3/8d | 2.7 | 18.1 | 67.1 |
| Host . | % Reduction in positive cells after α-ASGM-1 depletion . | ||
|---|---|---|---|
| CD8+ . | CD8+ASGM1+ . | DX5+ . | |
| Naive | 17.5 | 20.1 | 55.3 |
| Sp3/8d | 2.7 | 18.1 | 67.1 |
Percentage of reduction in the number of ex vivo CD8+, CD8+ASGM-1+, and DX5+ cells per spleen after α-ASGM-1 depletion. Splenocytes were directly labeled with α-CD8–PE, α-ASGM-1 followed by FITC-conjugated α-rabbit IgG, or α-DX5–PE and were analyzed by FACS.